Literature DB >> 4948768

Levodopa and orphenadrine hydrochloride in Parkinsonism.

R K Whyte, K R Hunter, D R Laurence, G M Stern, P Armitage.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 4948768     DOI: 10.1007/BF00568893

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  6 in total

1.  Combined treatment of parkinsonism with L-dopa and amantadine.

Authors:  K R Hunter; G M Stern; D R Laurence; P Armitage
Journal:  Lancet       Date:  1970-09-12       Impact factor: 79.321

2.  Amantadine in parkinsonism.

Authors:  K R Hunter; G M Stern; D R Laurence; P Armitage
Journal:  Lancet       Date:  1970-05-30       Impact factor: 79.321

3.  L-dopa in idiopathic parkinsonism.

Authors:  D B Calne; G M Stern; A S Spiers; D R Laurence
Journal:  Lancet       Date:  1969-11-08       Impact factor: 79.321

4.  L-dopa treatment failure: explanation and correction.

Authors:  L Rivera-Calimlim; C A Dujovne; J P Morgan; L Lasagna; J R Bianchine
Journal:  Br Med J       Date:  1970-10-10

5.  Evaluation of L-dopa therapy in Parkinson's disease.

Authors:  R J Mones; T S Elizan; G J Siegel
Journal:  N Y State J Med       Date:  1970-09-15

6.  Reversal by levodopa of cholinergic hypersensitivity in Parkinson's disease.

Authors:  M I Weintraub; M H Van Woert
Journal:  N Engl J Med       Date:  1971-02-25       Impact factor: 91.245

  6 in total
  4 in total

Review 1.  Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment.

Authors:  B K Young; R Camicioli; L Ganzini
Journal:  Drugs Aging       Date:  1997-05       Impact factor: 3.923

Review 2.  Striatal cholinergic interneuron regulation and circuit effects.

Authors:  Sean Austin O Lim; Un Jung Kang; Daniel S McGehee
Journal:  Front Synaptic Neurosci       Date:  2014-10-21

Review 3.  Targeting the cholinergic system in Parkinson's disease.

Authors:  Changliang Liu
Journal:  Acta Pharmacol Sin       Date:  2020-03-04       Impact factor: 6.150

Review 4.  Anticholinergics for symptomatic management of Parkinson's disease.

Authors:  R Katzenschlager; C Sampaio; J Costa; A Lees
Journal:  Cochrane Database Syst Rev       Date:  2003
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.